Objective. To determine if ultrasonography (US) and power Doppler (PD) may be useful in identifying polymyalgia rheumatica (PMR) patients with relapsing disease. Methods. For a mean of 41 months, 57 consecutive untreated patients with PMR were prospectively assessed for relapses/recurrences. This cohort represented all the patients diagnosed over a 18-month period in one Italian secondary referral centre. Clinical signs and symptoms as well as ESR and CRP were evaluated. US examination of the shoulders was performed in all 57 patients at diagnosis and after the onset of prednisone treatment (mean 24 AE 3 weeks). Power Doppler ultrasonography (PDUS) was performed in 24 patients. Shoulder sonograms were obtained according to standardized techniques. Results. Prednisone therapy significantly reduced the frequency and the degree of subacromial/subdeltoid bursitis, long head biceps tenosynovitis and glenohumeral synovitis. At diagnosis, a positive PD signal was observed more frequently in the subacromial/subdeltoid bursae (33%). Prednisone therapy significantly reduced the frequency of patients with positive PD signal. Of the 44 patients in remission or with low disease activity at the time of the second US, 26 (59%) still had evidence of persistent inflammatory lesions. There was no association between the persistence of inflammation at US and relapses/recurrences; in contrast, a positive PD signal at diagnosis was significantly associated with the occurrence of relapses/recurrences at follow-up. Conclusion. Subclinical inflammation detected by US persists in most PMR patients despite glucocorticoid treatment. PDUS may be useful to detect at diagnosis the patients with most active inflammation who have a higher risk of relapses/recurrences.
Introduction
Ultrasonography (US) and MRI have been used in PMR to detect inflammation in proximal joints and periarticular structures. Bilateral subacromial/subdeltoid bursitis and trochanteric bursitis are the most frequent lesions, being found in almost all PMR patients with pain in the shoulder and pelvic girdles [1] [2] [3] [4] [5] [6] [7] .
Usually, PMR patients respond rapidly to glucocorticoid (GC) treatment with complete or near-complete resolution of musculoskeletal aches and stiffness within a few days. The needed duration of GC therapy is variable, but in most patients it can be discontinued within 1-2 years. Some patients have a chronic relapsing course and may require low doses of GC for several years [1] .
The aim of this study was to evaluate the usefulness of US and power Doppler US (PDUS) as predictor of relapses/recurrences using detailed follow-up information from a prospectively studied cohort of patients with pure PMR.
Patients and methods

Patients
Sixty-six consecutive untreated patients with pure PMR [8] , representing all the patients diagnosed over an 18-month period in an Italian rheumatology secondary referral centre were prospectively assessed. Patients with clinical manifestations of giant cell arteritis (GCA) or with a positive temporal artery biopsy, and patients treated with GC prior to study entry were excluded. During the follow-up period, nine patients developed RA [9] and were thus excluded from the study. Fifty-seven patients whose PMR diagnosis was confirmed at the end of follow-up were included in this study.
After the first visit, all patients were treated with prednisone at an initial dosage of 12.5 mg/day. In the absence of a satisfactory clinical response, the initial dosage was increased by 2.5-5 mg/day. The median starting dosage of prednisone was 12.5 mg/day (range 12.5-17.5 mg/day). Prednisone was tapered in all patients according to the same fixed schedule, starting after 1 month of therapy if symptoms had resolved.
The patients were clinically assessed by the same rheumatologists (C.S. and M.G.C.) who were blinded to the ultrasonographic findings at presentation, once monthly for the first 6 months, and then every 3 months during the follow-up period. A standardized data collection form was used at every visit to record medical information, as described previously [10] . At each visit, Leeb's disease activity score (DAS) was calculated [11] .
Relapses and recurrences were defined as reappearance of clinical manifestations associated with elevated ESR or CRP (ESR >30 mm/1st h or CRP >0.5 mg/dl) in patients receiving GC and after discontinuation of treatment, respectively. Flares and relapses were treated by increasing prednisone dose or restarting prednisone, respectively. After the second US examination, the patients were followed up for at least 12 months and the number of disease relapses/recurrences was recorded. The study was reviewed and approved by the local ethics committee (Ethics Committee of Reggio Emilia Hospital). Written informed consent was obtained from all participating patients.
Laboratory analysis
Serial blood samples were collected concomitantly to clinical evaluation at the start of therapy, at monthly intervals for the first 6 months and subsequently at 3-month intervals until the end of follow-up. ESR was determined using the Westergren method. CRP was measured by nephelometry (NA latex CRP Kit, Behringwerke, Marburg, Germany; upper limit of the normal reference range 0.5 mg/dl).
Shoulder US
Bilateral shoulder US was performed in all patients before starting GC therapy, and at 24 weeks (AE3 weeks) after the onset of prednisone. The equipment used for US was the Siemens Acuson Antares (Siemens, Erlangen, Germany) machine with a 5-13 MHz linear array transducer. All US examinations were performed by the same rheumatologist (P.M.) with expertise in musculoskeletal US who was blinded to the clinical evaluation of the patients. Shoulder sonograms were obtained according to standardized techniques on the same day of the clinical examination [12] [13] [14] . Ultrasonographic signs of inflammation were the following: a hypoechoic distension >2 mm of subacromial/ subdeltoid bursae; >3.8 mm in the axillary recess of the glenohumeral joint or >2.0 mm in the posterior joint space; and >1.4 mm of the bicipital tendon sheath.
Rotator cuff tendons were also assessed for the presence of total and partial tears as well as for calcifications in longitudinal and transverse planes with both static and dynamic scanning. The humeral head was examined for the presence of erosions. PD assessment of the long head biceps tendon sheath, subacromial/ subdeltoid bursae and axillary and posterior recesses was carried out with settings standardized to a pulse repetition frequency of 390-500 Hz and low wall filter. PD gain was adjusted to a level just below the disappearance of colour sign under the bony cortex. The presence of a PD signal in/around the long head of biceps tendon and its sheath, subacromial/subdeltoid bursae and glenohumeral joint was considered positive.
Statistical analysis
Values were expressed as mean AE S.D. unless noted otherwise. Statistical analysis was done using SPSS statistical package (SPSS, Chicago, IL, USA). Chi-squared, Mann-Whitney and paired Wilcoxon two-tailed tests were computed to compare proportions and means. Statistical significance was evaluated at the 0.05 level.
Results
The demographic and clinical characteristics of the 57 patients are shown in Table 1 . Table 2 shows the results of shoulder US examination. At least one US sign of inflammation (subacromial/subdeltoid bursitis, long head biceps tenosynovitis or glenohumeral joint synovitis) was present at diagnosis in 56 (98.2%) patients; it was bilateral in 48 (84.2%).
Basal ultrasonographic findings
Subacromial/subdeltoid bursitis was detected by US in 52 (91.2%) patients, glenohumeral joint synovitis was observed in 20 (35.1%) and long head biceps tenosynovitis in 56 (98.2%).
Clinical, laboratory and ultrasonographic findings at the time of the second shoulder US Clinical and laboratory findings. A second US examination was performed after the beginning of prednisone treatment (mean 24 AE 3 weeks). At the time of the second US, Leeb's DAS Shoulder US findings. Table 2 shows the results of shoulder US at diagnosis and at the time of the second US examination. The prevalence of at least one sign of inflammation at US was significantly reduced at the time of the second examination. The frequency of monolateral inflammatory signs increased, because in 14 patients inflammation resolved after prednisone treatment in one shoulder only.
Prednisone therapy significantly reduced the frequencies of subacromial/subdeltoid bursitis, bilateral glenohumeral synovitis and left long head biceps tenosynovitis. The maximal distension of these three structures was also significantly reduced at the second US.
PDUS was performed at diagnosis and at the time of the second examination in 24 patients. A positive PD signal at diagnosis was observed more frequently in the subacromial/subdeltoid bursae. In the subacromial/subdeltoid bursae and in all three structures globally considered, the frequencies of patients with positive PD signals were significantly reduced by prednisone therapy. At the time of the second PDUS, only one patient had evidence of persistently positive PD signal in subacromial/subdeltoid bursae and glenohumeral joint.
Patients in clinical remission/low disease activity at the time of the second US: comparison between patients with and without evidence of inflammation at US
Of the 44 patients in remission (Leeb's DAS: 0-1.5) or with low disease activity (Leeb's DAS: 1.5-7) at the time of the second US, 26 (59.1%) had persistent inflammation on US despite a good clinical response to GC treatment, whereas 18 (40.9%) had no evidence of inflammation at US.
Comparing these two groups of patients, there were no significant differences in terms of clinical findings and laboratory data at the time of diagnosis and at the time of the second US except for systemic manifestations at diagnosis, which were significantly more frequent in patients with persistent inflammation (61.5 vs 16.7%, P ¼ 0.005).
Leeb's DAS at diagnosis and at the time of the second US were similar in the two groups of patients (37.7 AE 14.3 vs 36.4 AE 14.2, P ¼ NS and 2.4 AE 1.9 vs 2.4 AE 1.8, P ¼ NS, respectively). The frequencies of patients with at least one relapse/recurrence (27.7 vs 38.5%) and with at least two relapses/recurrences (11.1 vs 23.1%) at follow-up after the second US were not statistically different in the two groups. The patients with persistent inflammation at US had a significantly higher frequency of bilateral glenohumeral synovitis at diagnosis (27 vs 0%, P ¼ 0.03). In this group of patients, the frequencies of bilateral subacromial/ subdeltoid bursitis and bilateral long head biceps tenosynovitis at diagnosis were also higher (73 vs 44% and 85 vs 61%, respectively), but these differences were not statistically significant.
Comparison between patients with and without evidence at diagnosis of increased PD signal in articular and/or periarticular shoulder structures At diagnosis, 11 patients had positive PD signal and 13 had no signal. ESR values at diagnosis were significantly higher in the patients with positive PD signal (69 AE 23 vs 47 AE 15 mm/1st h, P ¼ 0.01). The patients with a positive PDUS signal in articular and periarticular synovial shoulder structures at diagnosis had a significantly higher frequency of relapses/recurrences after the second US as compared with the patients without evidence of PDUS signal (63.6 vs 15.4%, P ¼ 0.03). Relapses/recurrences were also more frequent in patients with bilaterally positive PDUS signal at diagnosis compared with those without (80.0 vs 26.3%, P ¼ 0.04). No significant differences were found in the other clinical, demographical and laboratory parameters (data not shown).
Discussion
To our knowledge, this is the first prospective longitudinal study evaluating US shoulder findings in PMR patients before and after the onset of GC treatment. We found that GC treatment was able to reduce the inflammatory lesions of periarticular and articular shoulder structures. In particular, the frequency of bilateral subacromial/subdeltoid bursitis and the degree of subacromial/ subdeltoid bursal maximal distension significantly decreased after the GC treatment. The improvement in US findings paralleled with the resolution of musculoskeletal manifestations and with the reduction in acute phase reactant levels. Similar results have been previously reported by our group in a smaller series of PMR patients using MRI [15] . The findings of this study thus confirm our previous observations that PMR is prevalently characterized by inflammation of extra-articular synovial structures [3] .
However, after a mean of 24 weeks of prednisone treatment, almost 60% of the PMR patients judged to be in complete clinical remission or with low disease activity had evidence of persistent inflammation by US criteria, predominantly in the extra-articular synovial structures of the shoulders. These results provide further evidence that GCs do not fully suppress inflammation in a subset of patients with PMR despite adequately controlling clinical manifestations. The frequency of relapses/recurrences over the study period was similar in patients with or without persistent US shoulder inflammation at follow-up. It is indeed unclear whether persistent shoulder inflammation as detected by US is related to the pathophysiological mechanisms involved in relapses/recurrences in PMR. Wagner et al. [16] demonstrated that circulating monocytes in PMR and GCA are activated and express IL-6-specific mRNA. Therefore, the risk of having relapses in PMR may be related more to generalized persistent systemic inflammation with overproduction of IL-6 rather than to localized (peri-)articular inflammation detected by US [17, 18] . PDUS allows to assess synovial vascularity. Increased PD signal reflects increased vascularity, which is known to occur in active inflammation [19] [20] [21] [22] . In our study, a positive PD signal at diagnosis was more frequently observed in the subacromial/ subdeltoid bursae than in the long head of the biceps or the shoulder joint, providing further evidence that bursitis is the hallmark inflammatory lesion in PMR [3] .
Prednisone treatment was able to control synovial hypervascularity in our patients. In fact, a positive synovial PD signal persisted in only one patient at the second US. However, a positive PD signal at diagnosis correlated with occurrence of relapses/recurrences during the follow-up. Therefore, PDUS may be useful to detect at diagnosis those patients with most active inflammation who have a higher risk of developing relapses/recurrences during the disease course.
If the prognostic role of PDUS examination as predictor of relapses/recurrences will be confirmed in other studies, the evidence of a positive PD signal at diagnosis may be used as a marker of disease severity. Evidence is accumulating that certain medications, in particular MTX, could be efficacious as steroidsparing agents in PMR [10, 23] . Treating more aggressively from the very beginning with steroid-sparing agents patients with a positive PD could potentially reduce global GC exposure and thus the risk of GC-related adverse events.
There were several limitations to our study. First, the limited sample size of patients with relapses/recurrences somewhat reduced the statistical power of this analysis. Secondly, we are aware that the inclusion of an age-matched healthy control group would have strengthened the findings of this study. However, in a previous case-control study by our group, no evidence at shoulder MRI of fluid collection in joints, bursae or sheaths of the long head of the biceps was observed in 10 age-matched healthy controls [2] .
In conclusion, persistent subclinical inflammation, predominantly involving extra-articular structures, is present in almost 60% of the PMR patients in complete remission or with low disease activity after 6 months of GC treatment. However, while persistent subclinical inflammation detected by US cannot be used to predict a relapsing disease course, the presence of a positive PD signal at diagnosis was found to correlate with the occurrence of relapses/recurrences during the follow-up.
Rheumatology key messages
Subclinical inflammation detected by US persists in most PMR patients despite glucocorticoid treatment. The presence at diagnosis of a positive PD signal correlates with the occurrence of relapses/recurrences.
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